Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Mascarenhas

Showing results (1-10 of 250) with videos related to

Pageof 25
Sort By:
Best Practice & Research. Clinical Haematology|September 6, 2014
Rationale for combination therapy in myelofibrosisJohn Mascarenhas
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative NeoplasmsJohn Mascarenhas
Blood|December 2, 2021
Mutations in MPNs to "interfere-on"John Mascarenhas
Leukemia & Lymphoma|January 15, 2015
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosisJohn Mascarenhas
Hematology. American Society of Hematology. Education Program|December 6, 2015
Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosisJohn Mascarenhas
The Lancet. Haematology|February 5, 2020
Interferon-α: alternative first- or second-line therapeutic option for polycythaemia veraJohn Mascarenhas
Expert Review of Hematology|August 19, 2022
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopeniaJohn Mascarenhas
Blood Advances|May 29, 2026
Interferon in early MF: intersection of biology and evidenceJohn Mascarenhas
Expert Opinion on Emerging Drugs|February 27, 2018
Emerging drugs for the treatment of MyelofibrosisAditya Shreenivas, John Mascarenhas
Hemasphere|November 15, 2019
Myelofibrosis-Related Anemia: Current and Emerging Therapeutic StrategiesLeonard Naymagon, John Mascarenhas
Pageof 25

Showing results (1-10 of 250) with videos related to

Sort By:
Pageof 25
Best Practice & Research. Clinical Haematology|September 6, 2014
Rationale for combination therapy in myelofibrosisJohn Mascarenhas
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative NeoplasmsJohn Mascarenhas
Blood|December 2, 2021
Mutations in MPNs to "interfere-on"John Mascarenhas
Leukemia & Lymphoma|January 15, 2015
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosisJohn Mascarenhas
Hematology. American Society of Hematology. Education Program|December 6, 2015
Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosisJohn Mascarenhas
The Lancet. Haematology|February 5, 2020
Interferon-α: alternative first- or second-line therapeutic option for polycythaemia veraJohn Mascarenhas
Expert Review of Hematology|August 19, 2022
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopeniaJohn Mascarenhas
Blood Advances|May 29, 2026
Interferon in early MF: intersection of biology and evidenceJohn Mascarenhas
Expert Opinion on Emerging Drugs|February 27, 2018
Emerging drugs for the treatment of MyelofibrosisAditya Shreenivas, John Mascarenhas
Hemasphere|November 15, 2019
Myelofibrosis-Related Anemia: Current and Emerging Therapeutic StrategiesLeonard Naymagon, John Mascarenhas
Pageof 25